Taylor Mertz, MD
Family Medicine · Moorhead, MNNPI 1285926360
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $176,231 of the $176,265 with a category attached, or 100.0%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 99.7% of it on its own, with 2 other manufacturers making up the rest. Among family medicine clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $2448.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$176K
- Shire North American Group Inc$475
- Exact Sciences$34
What the payments were for
- Consulting fees$176,231100%
- Food & beverage$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 70 | $175,756 |
| Shire North American Group Inc | 1 | $475 |
| Exact Sciences | 1 | $34 |
How this compares
$176,265 in reported general payments places this provider in the 95th percentile of 1,162 family medicine providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $101,214 |
| JardianceEmpagliflozin | 93 | $94,209 |
| EliquisApixaban | 56 | $50,227 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $26,992 |
| XareltoRivaroxaban | 33 | $26,650 |
| MounjaroTirzepatide | 17 | $18,675 |
| FarxigaDapagliflozin Propanediol | 12 | $12,406 |
| Victoza 3-PakLiraglutide | 16 | $12,288 |
| TrulicityDulaglutide | 12 | $10,920 |
| MyrbetriqMirabegron | 21 | $9,448 |
| Atorvastatin Calcium | 436 | $7,267 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $7,059 |
| Losartan Potassium | 246 | $4,306 |
| Metoprolol Succinate | 143 | $3,107 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,105 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Moorhead
- Allan LuistroMoorhead$5K
- Amanda LovoldSt Cloud$387K
- Robert MarshMinnetonka$300K
- Justin YoungTracy$93K
- Gerard SpoelhofDuluth$75K
- Martha MasciopintoCottage Grove$50K
- Glenn DetlefsenRosemount$39K
- Amy GilbertSaint Paul$27K
- Kevin PetersonMinneapolis$25K
- Joseph McGrathWabasha$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.